HomeMBIO • NASDAQ
add
Mustang Bio Inc
Previous close
$0.24
Day range
$0.21 - $0.25
Year range
$0.21 - $8.17
Market cap
2.72M USD
Avg Volume
1.97M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
| (USD) | Mar 2024info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 5.23M | -67.95% |
Net income | -5.19M | 68.90% |
Net profit margin | — | — |
Earnings per share | -0.46 | 77.67% |
EBITDA | -4.95M | 68.23% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Mar 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 1.34M | -97.70% |
Total assets | 14.59M | -80.18% |
Total liabilities | 19.54M | -55.39% |
Total equity | -4.94M | — |
Shares outstanding | 12.51M | — |
Price to book | -0.50 | — |
Return on assets | -80.89% | — |
Return on capital | -34,873.33% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2024info | Y/Y change |
|---|---|---|
Net income | -5.19M | 68.90% |
Cash from operations | -5.32M | 70.12% |
Cash from investing | — | — |
Cash from financing | 49.00K | — |
Net change in cash | -5.27M | 70.40% |
Free cash flow | -3.35M | 72.09% |
About
Mustang Bio is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Worcester, MA, U.S. Operating as a partner company of Fortress Biotech, Mustang Bio develops CAR-T immunotherapies and gene therapies for multiple diseases, including hematologic cancers, solid tumors, and X-linked severe combined immunodeficiency. Wikipedia
Founded
2015
Headquarters
Website
Employees
80
